New clinical trial upcoming using cyclodextrin as active

Nov 11, 2022Tamas Sohajdacarbohydratesalzheimers, clinical trial, fda, neurodegenerative diseases

Cyclo Therapeutics, Inc. sponsors Phase II trial for early Alzheimer’s disease. The study will enroll approximately 90 male and female patients aged 50 to 80 years who will be given a minimum active dose of 500 mg/kg of Trappsol Cyclo (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days for 6 months.
We wish the best of success to our colleagues at Cyclo Therapeutics and hope this therapy will prove useful for the benefit of these patients.
Having programs ourselves in developing NCEs for neurodegenerative diseases, we find this study particularly essential.

Scientific road trip in France

Nov 11, 2022Tamas Sohajdanewsfrance, milo malanga, road trip

Recently, our CSO, Milo Malanga had the privilege to deliver a talk about using cyclodextrins in biotechnology at the annual meet of the French Cyclodextrin Society (http://www.clubcyclodextrines.fr/en) and visit several prestigious labs in France to discuss strategic, long-term research collaborations. Thank you for hosting us Sophie Fourmentin at Université du Littoral Côte d’Opale, Bernard Martel at University of Lille 1 Sciences and Technology, Eric Monflier and Sebastien Tilloy at Université d’Artois and Matthieu Sollogoub at Sorbonne Université.

Stabilization of proteins with cyclodextrins

Nov 10, 2022Tamas Sohajdacarbohydrates, drug deliveryaggregation, formulation development, monoclonal antibodies, protein research, stability

Have you ever tried using cyclodextrin to prevent protein folding and to stabilize them with such safe excipients instead surface active agents? From the patent of Tamas Sohajda, our board member, you can learn more about this potential.

See the patent on Patentscope

Selectively Imprinted β-cyclodextrin Polymer for Colorimetric Assay of Lysophosphatidic Acid for Point of Care Detection of Ovarian Cancer

Nov 10, 2022Tamas Sohajdacarbohydratescancer diagnostics, cancer therapy, diagnosis

Cyclodextrin in diagnostics? Why not? Chaudhary Charan Singh University (NAZIA TARANNUM, Deepak Kumar, Yeshvandra Verma) presents Selectively Imprinted β-cyclodextrin Polymer for Colorimetric Assay of Lysophosphatidic Acid for Point of Care Detection of Ovarian Cancer

Read the full article here

The effect of different degrees of substitution in the case of (2-hydroxypropyl) beta-cyclodextrin

Nov 10, 2022Tamas Sohajdadrug deliveryformulation development

We have known for a long time (at least since our CSO Milo‘s paper “Back to the Future”: A New Look at Hydroxypropyl Beta-Cyclodextrins that the degree of substitution (DS) plays a critical role in cyclodextrin complexation. Now Qiang Fu’s team from Shenyang Pharmaceutical University shares further proof of this by comparing HPBCDs from different sources.

As pharmacopeias currently allow a very wide range of acceptable DS and different types of HPBCDs are available on the market (just compare Kleptose HP and Kleptose HPB from Roquette as an example), this is something certainly to investigate when developing new products.

Articles

https://www.sciencedirect.com/science/article/abs/pii/S0167732222016440?via%3Dihub

https://jpharmsci.org/article/S0022-3549(16)41410-3/fulltext

Prostate-specific membrane antigen (PSMA) ligands comprising an amylase cleavable linker

Nov 10, 2022Tamas Sohajdacarbohydrates, drug discoveryadc, glycotime, targeted therapy

Using sugars in a prodrug concept is a fascinating idea as these compounds can bring so much to the table like improve stability, PK, or help in targeting. In this patent from Heidelberg University oligosaccharide conjugated prostate-specific membrane antigens are described where the bonds are cleaved by amylase in the body.

See the patent on espacenet

Various effects of the novel product, “Nanochitin”, prepared from crab shells, on the skin

Nov 10, 2022Tamas Sohajdacarbohydrates, drug developmentglycotime

Oral, topical, and agrochemical uses of nanochitin presented by Shinsuke Ifuku from Tottori University.

See the full article

glycoforum.25A10

Cyclodextrin-based delivery systems in parenteral formulations: A critical update review

Nov 10, 2022Tamas Sohajdacarbohydratesformulation development

We truly believe in the potential cyclodextrin hold in drug delivery in traditional formulations and upcoming applications like protein and oligonucleotide delivery, controlled or targeted release, and nanotechnology. Of course, our research is closer to the latter applications.
In this review published by Universidade de Coimbra (Laura Ferreira, Joana Campos, Francisco Veiga Catarina Cardoso, and Ana Cláudia Paiva-Santos), parenteral applications and their potential a summarized very well.
Great educative read!

Design, Synthesis, and Characterization of Stapled Oligosaccharides

Nov 10, 2022Tamas Sohajdacarbohydrateschemistry, enzyme, medicinal chemistry, synthesis

From peptides to sugars: Design, Synthesis, and Characterization of Stapled Oligosaccharides. Oligosaccharide stapling increases enzymatic stability and cell penetration, opening new opportunities for using glycans in medicinal chemistry. – Max Planck Institute Manuel Garcia Ricardo, Emelie Ellen Reuber, Ling Yao, José Angel Danglad-Flores, Martina Delbianco, Peter Seeberger
Wonderful chemistry and insightful new possibilities.

See the full article here

VaporSPOT: Parallel Synthesis of Oligosaccharides on Membranes

Nov 9, 2022Tamas Sohajdacarbohydratesglycotime

Peter Seeberger, Felix Loeffler et al. from Max Planck Institute of Colloids and Interfaces published a #chemical vapor glycosylation strategy (VaporSPOT) that enables the simultaneous #synthesis of oligosaccharides on a cellulose #membrane.
Amazing study!
Full article: https://pubs.acs.org/doi/10.1021/jacs.2c07285